Voriconazole description: Difference between revisions
Ahmed Zaghw (talk | contribs) (Created page with "__NOTOC__ {{Voriconazole}} {{CMG}}; {{AE}} {{AZ}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VFEND (VORICONAZOLE) TABLET, FILM COATED VFEND ...") |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}} | ||
==Description== | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VFEND (VORICONAZOLE) TABLET, FILM COATED VFEND (VORICONAZOLE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION VFEND (VORICONAZOLE) POWDER, FOR SUSPENSION [ROERIG] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce3ef5cf-3087-4d92-9d94-9eb8287228db | publisher = | date = | accessdate = }}</ref> | VFEND® (voriconazole), a triazole antifungal agent is available as a lyophilized powder for solution for intravenous infusion, film-coated tablets for oral administration, and as a powder for oral suspension. The structural formula is: | ||
{| | |||
|[[File:VORICONdecri.JPG|600px|thumb]] | |||
|} | |||
Voriconazole is designated chemically as (2R,3S)-2-(2, 4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol with an empirical formula of C16H14F3N5O and a molecular weight of 349.3. | |||
Voriconazole drug substance is a white to light-colored powder. | |||
VFEND I.V. is a white lyophilized powder containing nominally 200 mg voriconazole and 3200 mg sulfobutyl ether beta-cyclodextrin sodium in a 30 mL Type I clear glass vial. | |||
VFEND I.V. is intended for administration by intravenous infusion. It is a single-dose, unpreserved product. Vials containing 200 mg lyophilized voriconazole are intended for reconstitution with Water for Injection to produce a solution containing 10 mg/mL VFEND and 160 mg/mL of sulfobutyl ether beta-cyclodextrin sodium. The resultant solution is further diluted prior to administration as an intravenous infusion. | |||
VFEND Tablets contain 50 mg or 200 mg of voriconazole. The inactive ingredients include lactose monohydrate, pregelatinized starch, croscarmellose sodium, povidone, magnesium stearate and a coating containing hypromellose, titanium dioxide, lactose monohydrate and triacetin. | |||
VFEND for Oral Suspension is a white to off-white powder providing a white to off-white orange-flavored suspension when reconstituted. Bottles containing 45 g powder for oral suspension are intended for reconstitution with water to produce a suspension containing 40 mg/mL voriconazole. The inactive ingredients include colloidal silicon dioxide, titanium dioxide, xanthan gum, sodium citrate dihydrate, sodium benzoate, anhydrous citric acid, natural orange flavor, and sucrose.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VFEND (VORICONAZOLE) TABLET, FILM COATED VFEND (VORICONAZOLE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION VFEND (VORICONAZOLE) POWDER, FOR SUSPENSION [ROERIG] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce3ef5cf-3087-4d92-9d94-9eb8287228db | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 07:24, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Description
VFEND® (voriconazole), a triazole antifungal agent is available as a lyophilized powder for solution for intravenous infusion, film-coated tablets for oral administration, and as a powder for oral suspension. The structural formula is:
 |
Voriconazole is designated chemically as (2R,3S)-2-(2, 4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol with an empirical formula of C16H14F3N5O and a molecular weight of 349.3.
Voriconazole drug substance is a white to light-colored powder.
VFEND I.V. is a white lyophilized powder containing nominally 200 mg voriconazole and 3200 mg sulfobutyl ether beta-cyclodextrin sodium in a 30 mL Type I clear glass vial.
VFEND I.V. is intended for administration by intravenous infusion. It is a single-dose, unpreserved product. Vials containing 200 mg lyophilized voriconazole are intended for reconstitution with Water for Injection to produce a solution containing 10 mg/mL VFEND and 160 mg/mL of sulfobutyl ether beta-cyclodextrin sodium. The resultant solution is further diluted prior to administration as an intravenous infusion.
VFEND Tablets contain 50 mg or 200 mg of voriconazole. The inactive ingredients include lactose monohydrate, pregelatinized starch, croscarmellose sodium, povidone, magnesium stearate and a coating containing hypromellose, titanium dioxide, lactose monohydrate and triacetin.
VFEND for Oral Suspension is a white to off-white powder providing a white to off-white orange-flavored suspension when reconstituted. Bottles containing 45 g powder for oral suspension are intended for reconstitution with water to produce a suspension containing 40 mg/mL voriconazole. The inactive ingredients include colloidal silicon dioxide, titanium dioxide, xanthan gum, sodium citrate dihydrate, sodium benzoate, anhydrous citric acid, natural orange flavor, and sucrose.[1]
References
Adapted from the FDA Package Insert.